Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 30,000 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 30,000 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $98.68, for a total transaction of $2,960,400.00. Following the transaction, the chief executive officer directly owned 194,440 shares of the company’s stock, valued at approximately $19,187,339.20. This represents a 13.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Peetz also recently made the following trade(s):

• On Monday, August 10th, Christopher Peetz sold 20,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $98.92, for a total transaction of $1,978,400.00.
• On Monday, July 6th, Christopher Peetz sold 20,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $122.27, for a total transaction of $2,445,400.00.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock opened at $100.63 on Friday. The stock has a market capitalization of $6.53 billion, a price-to-earnings ratio of -6.92 and a beta of 0.49. Mirum Pharmaceuticals, Inc. has a one year low of $63.23 and a one year high of $130.00. The company’s 50-day simple moving average is $109.55 and its 200-day simple moving average is $101.74. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The firm had revenue of $176.24 million during the quarter, compared to the consensus estimate of $166.33 million. During the same period in the prior year, the firm earned ($0.12) earnings per share. The firm’s quarterly revenue was up 37.9% compared to the same quarter last year. Equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.31 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. HC Wainwright dropped their price target on Mirum Pharmaceuticals from $185.00 to $140.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Stifel Nicolaus set a $136.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. JPMorgan Chase & Co. boosted their target price on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, July 2nd. Wolfe Research assumed coverage on shares of Mirum Pharmaceuticals in a report on Tuesday, May 19th. They set an “outperform” rating and a $145.00 target price on the stock. Finally, UBS Group set a $137.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, August 27th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $137.31.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Cullen Frost Bankers Inc. acquired a new position in shares of Mirum Pharmaceuticals during the fourth quarter valued at $30,000. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Mirum Pharmaceuticals in the 4th quarter worth about $32,000. CIBC Private Wealth Group LLC acquired a new stake in shares of Mirum Pharmaceuticals in the 4th quarter worth about $32,000. Quantbot Technologies LP bought a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at about $33,000. Finally, Comerica Bank lifted its position in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares during the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.